PETER PANZARINO: Open Payments
NPI 1093798928 · MONTICELLO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,442 in 108 payments from 14 companies in 2025. Trend: 2023 $2,272 · 2024 $3,139 · 2025 $2,442
Food & beverage: $2,330Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $819 |
| Teva Pharmaceuticals USA, Inc. | 20 | $562 |
| Otsuka America Pharmaceutical, Inc. | 12 | $195 |
| Neurocrine BioSciences, Inc. | 6 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $110 |
| Axsome Therapeutics, Inc. | 5 | $96 |
| Janssen Pharmaceuticals, Inc | 5 | $94 |
| E.R. Squibb & Sons, L.L.C. | 4 | $82 |
| Vanda Pharmaceuticals Inc. | 3 | $82 |
| Indivior Inc. | 4 | $75 |
Products named: VRAYLAR, AUSTEDO XR, INGREZZA, CAPLYTA, ABILIFY ASIMTUFII, Auvelity, INVEGA SUSTENNA, REXULTI.
Industry payments across NY — which companies pay providers there.
